Royal Prince Alfred Hospital Royal Prince Alfred Hospital
Newborn Care

Australasian Neonatal Medicines Formulary

The drug guidelines and other documents in the Australasian Neonatal Medicines Formulary (ANMF) are produced after thorough review of the literature relevant to the use of each drug in the neonate.  They are constructed with a view to use of the medications within the New South Wales legal framework and within the medical environment of Newborn Intensive Care.  The guidelines are reviewed on a regular basis, but there is no claim that all current regulatory or safety warnings have been added.  Care should be taken that the most up to date version of ANMF is being used.  Although all care is taken in the production of these guidelines, no responsibility is accepted regarding the use of ANMF and no liability is accepted to any  consequences resulting from following the recommendations of this product.

PLEASE NOTE:  Formularies marked with an asterisk (*) are for exclusive use within the Neonatal Intensive Care at the Royal Prince Alfred Hospital and have not been reviewed by ANMF group.


 

Acetylcysteine

Aciclovir

Adenosine

Adrenaline infusion

Adrenaline IV bolus

Adrenaline nebulised

Albumin 4%

Albumin 20%

Alprostadil

Amikacin

Amoxicillin

Amphotericin

Amphotericin (Liposomal)

Ampicillin

Atropine

AziTHROMYCIN

Benzylpenicillin

Caffeine

Calcium Chloride

Calcium Gluconate

Calcium Oral

Cefalexin

CeFAZolin

cefOTAXIME

cefTAZIDIME

Chloral Hydrate

Chloramphenicol

Curosurf (Poractant)

Cyclopentolate eye drops

Dexamethasone

Diazoxide

Digoxin

DOBUTamine

DOPamine

ERYthromycin

FentaNYL

Ferrous Sulphate

Flecainide

Flucloxacillin

Fluconazole

Folic Acid

Folinic Acid

Furosemide

 

Fusidic Acid*

Ganciclovir

Gentamicin

Glucagon

Glucose 40%

Glycerol

Hepatitis B Immunoglobulin

Hepatitis B Vaccine

Hydrochlorthiazide

Hydrocortisone

Ibuprofen

Imipenem

Immunoglobulin

Indomethacin

Infrarix Hexa

Infloran

Insulin Hyperglycaemia

Insulin Hyperkalaemia

Isoprenaline Infusion

LevETIRAcetam

Liothyronine

Magnesium

Meropenem

Metronidazole

Midazolam

Milrinone

Morphine IV

Morphine Oral

Naloxone

Nitroprusside*

Noradrenaline Infusion

Normal Saline

Nystatin

Omeprazole

Oxybuprocaine eye drops

Pancuronium

Pantoprazole

Paracetamol

Pentavite

Phenobarbitone

Phenytoin

Phenylephrine Eye Drops

Phosphorus

Piperacillin

Prevenar

Propranolol (cardiovascular)

Propranolol (For Infantile Haemangioma)

Pyridoxone*

Ranitidine

Remifentanil

Resonium*

Rocuronium

Rotavirus Vaccine

Salbutamol

Sandostatin*

Sildenafil

Sodium Bicarbonate

Sodium Chloride 0.9%

Sodium Chloride 23.4%

Sotalol

Spironolactone

Sucrose

Sulfamethoxazole and Trimethoprim

Survanta (Beractant)

Suxamethonium

Synacthen (for test)*

Thyroxine (oral)

Timolol (Topical)

Topiramate

Ursodeoxycholic Acid

Valganciclovir

Vancomycin continuous infusion

Vasopressin

Vecuronium

Vitamin D

Vitamin K

Zidovudine IV*

Zidovudine Oral*  

 

 

 

© The State of New South Wales (NSW Health) 2019.
Unless otherwise stated, the contents of this publication are licensed under the Creative Commons Attribution-Noncommercial 4.0 licence, except as noted below. Terms and conditions of the licence can be viewed at https://creativecommons.org/licenses/by-nc/4.0/
We request attribution as © State of New South Wales (NSW Health) 2019.
We also request that you observe and retain any copyright or related notices that may accompany this material as part of the attribution.
Material not licensed under the Creative Commons Licence
The following material in this publication is not licensed under the Creative Commons Licence:
1. The State’s Coat of Arms and any other symbols, logos or trademarks of the State of NSW of any Department or Agency of the State (unless incidentally reproduced in using an unaltered document under the Creative Commons licence).
2. Any third-party material unless expressly stated to be published under the Creative Commons Licence. (Note that such material may not be expressly identified, although as a general policy we do aim to do so).

  
The State of New South Wales accepts no responsibility for any modification, redistribution or use of the formulary or any part thereof. The formulary is expressly intended for use by NSW Health staff when performing duties and delivering health care for, and on behalf of, NSW Health.
 Under no circumstances will the State of New South Wales, its employees or agents, be liable for any loss, injury, claim, liability or damages of any kind resulting from the unauthorised use of, or reliance upon the formulary or its contents.  

 

 


 

 

Disclaimer

 

 Copyright statement

 

For any content related matters on this section, please contact RPAH Neonatal Formulary Director, Dr David Osborn.